2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMaleMiddle AgedNeoplasm Recurrence, LocalPositron-Emission TomographyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseDevelopment of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Ross A, Sprenkle P. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Network Open 2024, 7: e2417274. PMID: 38874922, PMCID: PMC11179136, DOI: 10.1001/jamanetworkopen.2024.17274.Peer-Reviewed Original ResearchConceptsElectronic health recordsCancer diagnosisClinical data linkageMedicine Clinical TermsPatterns of careProstate cancer diagnosisRadical prostatectomyCancer risk stratificationData linkageHealth recordsClinical dataMain OutcomesCancer outcomesClinical juncturesClinical careCommon Procedural Terminology codesAdministrative dataDiagnosis codesLongitudinal clinical dataCohort studyPharmacy recordsGenomic classifierProcedural Terminology codesDevelopment of prostate cancer metastasisLinkage data
2023
Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy
Khajir G, Press B, Lokeshwar S, Ghabili K, Rahman S, Gardezi M, Washington S, Cooperberg M, Sprenkle P, Leapman M. Prostate cancer risk stratification using magnetic resonance imaging–ultrasound fusion vs systematic prostate biopsy. JNCI Cancer Spectrum 2023, 7: pkad099. PMID: 38085220, PMCID: PMC10733209, DOI: 10.1093/jncics/pkad099.Peer-Reviewed Original ResearchConceptsMagnetic resonance imaging-ultrasound fusionMRF-TBLow-risk diseaseSystematic biopsyLower riskRisk groupingProstate biopsyActive surveillanceHigh riskProstate cancer risk stratificationIntermediate-risk criteriaIntermediate-risk diseaseSystematic prostate biopsyCancer risk stratificationPrimary study objectiveNCCN guidelinesImage-guided approachLocalized cancerRisk stratificationBenign findingsProstate cancerClinical riskDiagnostic yieldRetrospective analysisBiopsyNCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023.
Moses K, Sprenkle P, Bahler C, Box G, Carlsson S, Catalona W, Dahl D, Dall'Era M, Davis J, Drake B, Epstein J, Etzioni R, Farrington T, Garraway I, Jarrard D, Kauffman E, Kaye D, Kibel A, LaGrange C, Maroni P, Ponsky L, Reys B, Salami S, Sanchez A, Seibert T, Shaneyfelt T, Smaldone M, Sonn G, Tyson M, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi R, Freedman-Cass D. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. Journal Of The National Comprehensive Cancer Network 2023, 21: 236-246. PMID: 36898362, DOI: 10.6004/jnccn.2023.0014.Peer-Reviewed Original ResearchConceptsProstate cancer early detectionNCCN guidelinesCancer early detectionEarly detectionNCCN Guidelines InsightsNegative biopsy resultsEarly Detection ProgramSignificant prostate cancerIndolent diseaseBiopsy resultsAppropriate counselingProstate cancerMultiparametric MRIDetection programRecent updatesGuidelinesTesting protocol
2022
Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning.
Paulson N, Zeevi T, Papademetris M, Leapman MS, Onofrey JA, Sprenkle PC, Humphrey PA, Staib LH, Levi AW. Prediction of Adverse Pathology at Radical Prostatectomy in Grade Group 2 and 3 Prostate Biopsies Using Machine Learning. JCO Clinical Cancer Informatics 2022, 6: e2200016. PMID: 36179281, DOI: 10.1200/cci.22.00016.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyBiopsy, Large-Core NeedleEosine Yellowish-(YS)HematoxylinHumansMachine LearningMaleProstateProstatectomyProstatic NeoplasmsConceptsGrade group 2Prostate biopsyRadical prostatectomyAdverse outcomesGroup 2GG-2Core prostate biopsyProstate cancer outcomesPatient's clinical riskClinical risk assessmentCore needle biopsyOngoing clinical needAdverse outcome predictionRetrospective reviewAdverse pathologyCAPRA scoreEntire cohortCancer outcomesPathologic diagnosisNeedle biopsyClinical riskDisease outcomeProstate cancerBiopsyDisease oneMulti‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions
Fang AM, Shumaker LA, Martin KD, Jackson JC, Fan RE, Khajir G, Patel HD, Soodana‐Prakash N, Vourganti S, Filson CP, Sonn GA, Sprenkle PC, Gupta GN, Punnen S, Rais‐Bahrami S. Multi‐institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI‐RADS 3 lesions. Cancer 2022, 128: 3287-3296. PMID: 35819253, DOI: 10.1002/cncr.34355.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyHumansMagnetic Resonance ImagingMaleProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk FactorsConceptsPI-RADS 3 lesionsHigher prostate specific antigen densitySignificant prostate cancerProstate-specific antigen densityPrior negative biopsyNegative biopsyMagnetic resonance imagingProstate cancerPSA densityValidation cohortEquivocal lesionsAntigen densityResonance imagingMultivariable logistic regression modelData System (PI-RADS) 3 lesionsMultiparametric magnetic resonance imagingElevated PSA densityMulti-institutional analysisDecision curve analysisProstate Imaging ReportingDetection of csPCaLogistic regression modelsMultivariable analysisSubsequent biopsyTraining cohortClinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer
Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars And Original Investigations 2022, 40: 407.e21-407.e27. PMID: 35811206, DOI: 10.1016/j.urolonc.2022.06.005.Peer-Reviewed Original ResearchMeSH KeywordsHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesWatchful WaitingConceptsActive surveillanceIndex lesionProstate biopsyProstate cancerMultiparametric magnetic resonance imagingData System version 2Low-risk CaPSurveillance prostate biopsyGleason grade groupMultivariate logistic regressionSignificant prostate cancerProstate Imaging ReportingReceiver operator characteristic curvePI-RADS 2Low-suspicion lesionsOperator characteristic curveMagnetic resonance imagingHigher PSADOnly significant variablePrimary outcomeMultivariable analysisSystematic biopsyRetrospective analysisBiopsy approachImaging Reporting